XTAMPZA ER Drug Patent Profile

Which patents cover Xtampza Er, and when can generic versions of Xtampza Er launch?

Xtampza Er is a drug marketed by Collegium Pharm Inc and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-four patent family members in thirteen countries.

The generic ingredient in XTAMPZA ER is oxycodone. There are nineteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the oxycodone profile page.

DrugPatentWatch^® Generic Entry Outlook for Xtampza Er

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 9, 2028. This may change due to patent challenges or generic licensing.

There have been seven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are four tentative approvals for the generic drug (oxycodone), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for XTAMPZA ER

International Patents:	24
US Patents:	8
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	17
Clinical Trials:	2
Patent Applications:	1,860
Drug Prices:	Drug price information for XTAMPZA ER
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XTAMPZA ER
DailyMed Link:	XTAMPZA ER at DailyMed

See drug prices for XTAMPZA ER

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for XTAMPZA ER

NDA:

208090

Dosage:

CAPSULE, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for XTAMPZA ER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Alabama at Birmingham	Early Phase 1
Ajay Wasan, MD, Msc	Phase 4
Collegium Pharmaceutical, Inc.	Phase 4

See all XTAMPZA ER clinical trials

Pharmacology for XTAMPZA ER

Drug Class	Opioid Agonist
Mechanism of Action	Full Opioid Agonists

Paragraph IV (Patent) Challenges for XTAMPZA ER

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XTAMPZA ER	Extended-release Capsules	oxycodone	9 mg, 13.5 mg, 18 mg, 27 mg and 36 mg	208090	1	2017-11-15

US Patents and Regulatory Information for XTAMPZA ER

XTAMPZA ER is protected by eight US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-004	Apr 26, 2016		RX	Yes	No			Y
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-004	Apr 26, 2016		RX	Yes	No			Y
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-005	Apr 26, 2016		RX	Yes	Yes			Y
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-004	Apr 26, 2016		RX	Yes	No			Y
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-001	Apr 26, 2016		RX	Yes	No			Y
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-003	Apr 26, 2016		RX	Yes	No			Y
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-003	Apr 26, 2016		RX	Yes	No			Y

Expired US Patents for XTAMPZA ER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-004	Apr 26, 2016
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-005	Apr 26, 2016
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-003	Apr 26, 2016
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-003	Apr 26, 2016
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-001	Apr 26, 2016
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-004	Apr 26, 2016
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-004	Apr 26, 2016

International Patents for XTAMPZA ER

When does loss-of-exclusivity occur for XTAMPZA ER?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Cyprus

Japan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XTAMPZA ER around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2003247876	ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIODS AND OTHER DRUGS
Canada	2491572	COMPOSITIONS PHARMACEUTIQUES EMPECHANT LA CONSOMMATION ABUSIVE D'OPIOIDES ET D'AUTRES DROGUES (ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIODS AND OTHER DRUGS)
Canada	2569958	FORMULATIONS DE PREVENTION DES ABUS (ABUSE-DETERRENT DRUG FORMULATIONS)
Canada	2916869	FORMULATIONS DE PREVENTION DES ABUS (ABUSE-DETERRENT DRUG FORMULATIONS)
Cyprus	1119831
Denmark	1765292
European Patent Office	1594467	COMPOSITIONS PHARMACEUTIQUES D'OPIOIDES ET D'AUTRES MEDICAMENTS EMPECHANTS LES UTILISATIONS ABUSIVES (ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS)

Supplementary Protection Certificates for XTAMPZA ER

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1685839	92292	Luxembourg		PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE

XTAMPZA ER market dynamics and financial trajectory (THC-like analgesic, Purdue Pharma legacy, opioid market exposure)

Last updated: July 28, 2026

XTAMPZA ER (extended-release oxycodone) is an opioid analgesic with a mature, heavily genericized product category and a constrained near-term growth profile. The financial trajectory is driven by (1) opioid volume and payer controls, (2) substitution risk from lower-cost oxycodone ER products, (3) formulary access and REMS-driven prescribing behavior, and (4) Purdue Pharma’s post-bankruptcy restructuring and opioid settlement era supply chain and commercialization decisions. Net sales momentum has generally moved with broader US opioid demand, while market share and pricing have been pressured by generics and wholesaler contracting.

XTAMPZA ER revenue drivers and market dynamics: what moves sales year over year?

Bottom line: XTAMPZA ER sales are primarily a function of US chronic pain ER opioid prescribing, payer formulary placement, and price competition from generic oxycodone ER products. Growth tends to be modest unless there is a favorable formulary shift, a targeted payer win, or a supply/availability advantage versus competing ER oxycodones.

What market factors affect oxycodone ER volume and pricing?

Key dynamics that typically govern annual sales for ER oxycodone brands:

1. Formulary placement and step therapy

   • Payers frequently prefer lowest-cost ER opioids and require prior authorization for higher-tier brands.
   • Brand performance correlates with how often XTAMPZA ER is designated a preferred ER opioid option.

2. Wholesale buying patterns

   • In mature opioid markets, quarterly sales can reflect channel inventory swings rather than only end-demand.

3. Prescribing constraints and risk mitigation

   • REMS and tighter opioid risk management reduce “switching speed” from one product to another.
   • Prescriber behavior becomes less responsive to marketing as prescribers and health systems standardize on specific ER opioids.

4. Class-level opioid volume

   • Macro opioid consumption trends drive baseline ER opioid demand.
   • Reductions in high-risk prescribing and opioid stewardship campaigns change the addressable population over time.

How does substitution from generic oxycodone ER affect XTAMPZA ER?

XTAMPZA ER faces persistent substitution pressure:

• Therapeutic equivalence: ER oxycodone formulations are often treated as substitutable at the payer level.
• Price spread: Generics compress net price and limit brand ability to maintain share without strong payer contracts.
• Switching friction: Switching from one ER oxycodone to another can be administratively and clinically constrained, which can stabilize share short term, but long term economics typically erode brand premium.

What patents protect XTAMPZA ER and how does patent life drive financial trajectory?

Bottom line: XTAMPZA ER’s financial trajectory is shaped by the strength and remaining term of its Orange Book-listed patent estate (where listed) and by the time horizon for generic entry risk. In practice, the mature state of the oxycodone ER market implies that many key exclusivity and listed patents have already cleared or expired, leaving pricing power structurally constrained.

What is XTAMPZA ER’s legal exclusivity profile in the opioid ER category?

For established opioid ER products, financial outcomes after the main patent block usually follow:

• reduced brand premium,
• increased competition from AB-rated generics,
• and share shift toward lowest net cost products on formularies.

Patent estate impact on pricing power

When patent exclusivity weakens:

• Net price declines accelerate.
• Discounting and rebates often rise to preserve formulary position.
• Commercial spend may shift from expansion to defense of existing accounts.

(Orange Book listing and specific patent numbers are jurisdiction- and product-format dependent. A definitive patent-by-patent mapping is required to state expiration dates and which specific claims remain in force.)

When does XTAMPZA ER lose exclusivity and what generic entry risks exist?

Bottom line: For a legacy ER oxycodone brand, generic entry risk typically manifests early once listed exclusivity lapses. After entry, the brand’s commercial trajectory generally transitions from volume growth to share defense.

Post-exclusivity playbook for brands in ER opioid markets

After generics enter:

• sales become highly dependent on contracted payer preference rather than broad prescriber demand,
• the brand often focuses on patient continuity cohorts,
• and pricing strategy is driven by net-to-wholesaler and rebate arithmetic.

What is the Orange Book status of XTAMPZA ER and which filings target it?

Bottom line: Orange Book status drives the timing of Paragraph IV challenges and generic launches. The practical outcome is usually a step-change in market share once an abbreviated new drug application (ANDA) is approved for an AB-rated generic.

A precise Orange Book snapshot requires the product-specific Orange Book listing (strengths, dosage form, NDA holder, listed patents, and expiration dates). Without that exact listing, the status cannot be stated cleanly.

How does XTAMPZA ER compare with other oxycodone ER drugs for market share and payer strategy?

Bottom line: In payer decision frameworks, XTAMPZA ER competes in the ER oxycodone “equivalent” cluster, where brand differentiation is less durable than price and contracting. Comparative market dynamics are typically determined by:

• negotiated rebate structures,
• formulary tier position,
• and availability/supply reliability.

Competitive set typically includes other ER oxycodone products

Within the ER oxycodone arena, performance is influenced by:

• brand-to-generic mix across plans,
• whether competing products have stronger restricted distribution or formulary exclusivity,
• and how quickly generics capture preferred coverage.

What formulations are protected by XTAMPZA ER patents and what manufacturing/IP barriers stop generics?

Bottom line: For ER oxycodone brands, manufacturing and formulation patent coverage can slow generic adoption if claims cover specific delivery mechanisms, formulation parameters, or tamper resistance. In practice, generic barriers usually compress over time as ANDAs rely on bioequivalence standards and non-infringing manufacturing designs.

Why formulation patents matter in ER opioids

Formulation-claim scope impacts:

• whether generics can design around,
• whether complex processes increase generic cost,
• and whether generic entry faces “at-risk” launches while litigation is pending.

What patent litigation affects XTAMPZA ER and how do settlements change market timing?

Bottom line: In the US, the typical path after listed-patent expiration includes ANDA litigation that can delay launch dates through automatic stays or settlements. These events can create temporary brand stabilization, but usually do not reverse longer-term pricing compression once multiple generics are established.

How settlements typically affect financial trajectory

Settlements can:

• postpone launch dates,
• define an “authorized” generic entry structure,
• or create revenue-sharing arrangements. These deal terms determine the timing of market share transitions, which is reflected in annual net sales and volume.

A definitive litigation-and-settlement timeline requires docket-level identification of the specific cases involving XTAMPZA ER (NDA and ANDA numbers, paragraph IV dates, court jurisdictions, and final settlement terms).

FDA regulatory status for XTAMPZA ER: what pathway changes risk and access?

Bottom line: XTAMPZA ER’s FDA status determines:

• whether it is protected by listed patents,
• whether the brand is still actively marketed,
• and how quickly competing generics can enter once approved.

How FDA review and labeling affect payer adoption

Labeling that supports broad chronic pain use can keep the product usable for new starts. But in practice:

• payer and clinician standard-of-care rules dominate once generics are available,
• and REMS-era risk mitigation constrains broad prescribing shifts.

Commercial trajectory: what do the last 5 to 10 years of XTAMPZA ER sales patterns indicate?

Bottom line: XTAMPZA ER has followed a mature-brand profile consistent with a large opioid ER category: limited growth, sustained demand among stable cohorts, and gradual erosion of premium pricing as generic competition deepens.

Without audited revenue tables for XTAMPZA ER (NDA-specific net sales, prescriptions, and share metrics), a month-by-month or year-by-year financial trajectory cannot be stated with precision.

What KPIs best explain XTAMPZA ER financial trajectory

For operational and investment decisioning, the revenue model typically breaks into:

• Net revenue per unit (net price after rebates, discounts, and chargebacks)
• Units (prescriptions and conversion to tablets)
• Channel inventory (wholesaler restocking effects)
• Formulary coverage (plan counts and tier placement)
• Competitive intensity (number of AB-rated ER oxycodone competitors)
• Contracting dynamics (PBM and health-system deals)

Where is revenue exposure highest for XTAMPZA ER: payer classes and geography?

Bottom line: For an ER opioid brand, revenue is concentrated in the commercial and Medicare Part D markets where formulary management and rebate contracting determine net price. Medicaid participation patterns tend to be constrained by state formularies and preferred generic ER options.

Geographic allocation is generally US-wide; state-specific opioid policy can shift demand slightly but typically not enough to reverse the economics of generic substitution.

How strong is the patent estate for XTAMPZA ER versus generic oxycodone ER brands?

Bottom line: Generic penetration pressure usually overwhelms any residual brand premium once multiple AB-rated generics exist. Patent strength matters most for delaying the first wave and for preserving formulary “brand preferred” positioning during the transition period.

A quantitative strength assessment requires:

• remaining term per listed patent,
• scope of independent claims,
• litigation posture,
• and whether ANDA design-around is credible.

Without a patent-by-patent dataset for the XTAMPZA ER listing, a defensible strength ranking is not possible.

Generic launch scenarios for XTAMPZA ER: what happens if additional ANDAs enter?

Bottom line: Any incremental generic entrant typically accelerates:

• net price declines,
• share shifts toward the lowest-cost AB-rated products,
• and higher rebate pressure to maintain preferred tiers.

Likely post-entry outcomes

• Brand unit share stabilizes only if the brand retains special formulary carve-outs or contracts.
• Average net revenue per unit compresses first.
• Volume impact may be slower than price impact due to REMS and patient continuity.

Key Takeaways

• XTAMPZA ER’s commercial performance is dominated by US ER opioid demand, payer formulary placement, and generic oxycodone ER substitution pressure.
• The brand’s financial trajectory tends to shift from premium pricing to share defense once exclusivity clears and multiple AB-rated generics enter.
• Patent strength and litigation timing can delay specific waves of generic launch, but the mature oxycodone ER class economics generally cap long-term brand growth.
• Revenue exposure is concentrated in contracting-driven payer segments where net pricing and tier position drive outcomes.

FAQs

1. How do PBM rebate and formulary tier changes typically impact XTAMPZA ER net sales after generic entry?
2. What litigation timelines most commonly delay generic oxycodone ER launches when Orange Book patents remain in force?
3. How does REMS monitoring affect switching behavior among ER oxycodone products and brand unit demand?
4. What OTC or non-opioid analgesic substitutions most affect the demand pool for chronic pain ER opioid therapies?
5. How does authorized generic strategy differ from independent generic launch in how it impacts brand pricing for ER opioids?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-07-28).
2. FDA. Drug Approval Reports and Labeling (NDA records for XTAMPZA ER). (Accessed 2026-07-28).
3. United States Patent and Trademark Office (USPTO). Patent assignment and bibliographic records (for XTAMPZA ER-related patents). (Accessed 2026-07-28).